真实世界中测量慢性髓系白血病酪氨酸激酶抑制剂相关毒性效应:患者报告结局工具内容效度的系统综述与批判性评估
本系统综述检索PubMed和Embase(2017年1月1日至2022年10月21日),评估真实世界中用于测量慢性髓系白血病患者酪氨酸激酶抑制剂相关毒性效应的患者报告结局工具的内容效度。按COSMIN标准,六种已识别工具的内容效度均未被评为充分;其中五种因开发后未经专业人员评估、涉及慢性髓系白血病患者极少或遗漏关键症状而被评为不一致,证据质量从中等到极低。两种EORTC工具是唯一未遗漏关键毒性效应(如肌肉痉挛)的工具,但其相关性被评为不一致。本综述表明需要一种具有充分内容效度的工具来测量慢性髓系白血病患者酪氨酸激酶抑制剂治疗的毒性效应。
要点
- 六种已识别工具的内容效度按COSMIN标准均未被评为充分。
- 五种工具因开发后未经专业人员评估、慢性髓系白血病患者极少或遗漏关键症状被评为不一致。
- 两种EORTC工具未遗漏关键毒性效应,但相关性被评为不一致。
核心结论
- 本综述表明需要一种具有充分内容效度的工具来测量慢性髓系白血病患者酪氨酸激酶抑制剂治疗的毒性效应。
- 在此之前,利益相关者可依据本评估从当前使用的工具中做出知情选择。
研究设计与样本
- 系统综述,检索PubMed和Embase从2017年1月1日至2022年10月21日。
- 纳入在慢性髓系白血病患者中使用或为其开发、评估患者症状的工具的研究。
- 内容效度根据COSMIN标准评估。
主要发现
- 共识别六种工具,按COSMIN标准均未被评为内容效度充分。
- 五种工具(EORTC QLQ-CML24、EORTC症状集、FACT-LEU、HM-PRO、MDASI-CML)被评为不一致,原因包括开发后未经专业人员评估、涉及的慢性髓系白血病患者极少或遗漏关键症状。
- 上述评级基于中等质量至极低质量证据。
- 两种EORTC工具是唯一未遗漏关键毒性效应(如肌肉痉挛)的工具,但其相关性被评为不一致:QLQ-CML24包含健康相关生活质量问题,而症状集包含源自实体瘤治疗的条目。
关键数值与推荐
- 内容效度按COSMIN标准评估:六种工具均未被评为充分。
- 五种工具评为不一致:EORTC QLQ-CML24(24个条目)、EORTC症状集、FACT-LEU、HM-PRO、MDASI-CML。
- 两种EORTC工具未遗漏关键毒性效应(如肌肉痉挛),但相关性评为不一致。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Insight into real-world treatment-related toxic effects reported by patients has the potential to improve care, benchmark trials, and fill knowledge gaps, especially in patients with chronic myeloid leukaemia, which is treated in the majority of patients continually with tyrosine-kinase inhibitors (TKIs). The aim of our systematic review was to investigate the content validity of instruments that elicit TKI-related toxic effects reported by patients with chronic myeloid leukaemia in the real world. We searched PubMed and Embase from Jan 1, 2017 to Oct 21, 2022. Studies on instruments used in or developed for patients with chronic myeloid leukaemia that assess a patient's symptoms were eligible. Content validity was assessed according to the Consensus-Based Standards for the Selection of Health Measurement Instruments (COSMIN): none of the six identified instruments were rated as sufficient. Five instruments (European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire for chronic myeloid leukaemia with 24 items [EORTC QLQ-CML24], EORTC symptom set, Functional Assessment of Cancer Therapy-Leukaemia [FACT-LEU], haematological malignancies patient-reported outcomes [HM-PRO], and MD Anderson Symptom Inventory for chronic myeloid leukaemia [MDASI-CML]) were rated as inconsistent due to not being evaluated by professionals post-development, having very few patients with chronic myeloid leukaemia involved, or missing key symptoms. Moderate-quality to very low-quality evidence underpinned these ratings. The two EORTC instruments were the only ones not to miss key toxic effects (eg, muscle cramps). However, their relevance was rated as inconsistent: the QLQ-CML24 includes questions on health-related quality-of-life, whereas the symptom set includes items sourced from solid cancer treatments. This Review shows the need for an instrument with sufficient content validity to measure toxic effects from TKI treatment in patients with chronic myeloid leukaemia. Until then, stakeholders can make an informed choice from currently used instruments with our assessment.
引用
- Smit Y, Metsemakers SJJPM, Janssen JJWM, et al. Measuring chronic myeloid leukaemia TKI-related toxic effects in the real world: a systematic review and critical assessment of content validity of patient-reported outcome measures. Lancet Haematol. 2023. PMID: 37604177. doi:10.1016/S2352-3026(23)00173-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。